Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Josianne Nitcheu Tefit & Vincent Serra. (2011) Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Review of Vaccines 10:8, pages 1207-1220.
Read now
Read now
Philippe Fournier & Volker Schirrmacher. (2009) Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Review of Vaccines 8:1, pages 51-66.
Read now
Read now
Frédéric Lévy & Sara Colombetti. (2006) Promises and Limitations of Murine Models in the Development of Anticancer T-Cell Vaccines. International Reviews of Immunology 25:5-6, pages 269-295.
Read now
Read now
Articles from other publishers (33)
Brankica Filipić, Ivana Pantelić, Ines Nikolić, Dragomira Majhen, Zorica Stojić-Vukanić, Snežana Savić & Danina Krajišnik. (2023) Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines. Vaccines 11:7, pages 1172.
Crossref
Crossref
Qinnan Chen, Hongyu Shen, Fengqi Nie & Ming Sun. (2022) A Whole New Comprehension about ncRNA-Encoded Peptides/Proteins in Cancers. Cancers 14:21, pages 5196.
Crossref
Crossref
Woojong Lee & M. Suresh. (2022) Vaccine adjuvants to engage the cross-presentation pathway. Frontiers in Immunology 13.
Crossref
Crossref
Cheryl L.-L. Chiang & Lana E. Kandalaft. 2022. Cancer Vaccines as Immunotherapy of Cancer. Cancer Vaccines as Immunotherapy of Cancer
21
49
.
Sandra Santos-Sierra. (2020) Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry 401:4, pages 435-446.
Crossref
Crossref
Nazima Sultana, Pranita Bora & Bipul Sarma. 2020. Smart Nanocontainers. Smart Nanocontainers
159
178
.
Nor Azrini Nadiha Azmi, Amal A. M. Elgharbawy, Shiva Rezaei Motlagh, Nurhusna Samsudin & Hamzah Mohd. Salleh. (2019) Nanoemulsions: Factory for Food, Pharmaceutical and Cosmetics. Processes 7:9, pages 617.
Crossref
Crossref
Cheryl Lai-Lai Chiang & Lana E. Kandalaft. (2018) In vivo cancer vaccination: Which dendritic cells to target and how?. Cancer Treatment Reviews 71, pages 88-101.
Crossref
Crossref
Lan B. Hoang-Minh & Duane A. Mitchell. (2018) Immunotherapy for Brain Tumors. Current Treatment Options in Oncology 19:11.
Crossref
Crossref
Hossam H Tayeb & Frank Sainsbury. (2018) Nanoemulsions in drug delivery: formulation to medical application. Nanomedicine 13:19, pages 2507-2525.
Crossref
Crossref
Takumi Kumai, Aaron Fan, Yasuaki Harabuchi & Esteban Celis. (2017) Cancer immunotherapy: moving forward with peptide T cell vaccines. Current Opinion in Immunology 47, pages 57-63.
Crossref
Crossref
Haiyan Xu, Jie Meng, Qiang Ma & Xiaojin Li. 2016. Biomedical Applications and Toxicology of Carbon Nanomaterials. Biomedical Applications and Toxicology of Carbon Nanomaterials
357
396
.
Virgil E.J.C. Schijns, Chrystel Pretto, Laurent Devillers, Denis Pierre, Florence M. Hofman, Thomas C. Chen, Pascal Mespouille, Peter Hantos, Philippe Glorieux, Daniela A. Bota & Apostolos Stathopoulos. (2015) First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine 33:23, pages 2690-2696.
Crossref
Crossref
Shoiab Bukhari, Taseem A. Mokhdomi, Naveed A. Chikan, Asif Amin, Hilal Qazi, Sajad H. Wani, Asrar H. Wafai, Sumira Tyub, Farhat Mustafa, Masood S. Mir, Nisar A. Chowdri & Raies A. Qadri. (2015) Affinity proteomics led identification of vimentin as a potential biomarker in colon cancers: insights from serological screening and computational modelling. Molecular BioSystems 11:1, pages 159-169.
Crossref
Crossref
Marieke IG Raaijmakers, Sima Rozati, Simone M Goldinger, Daniel S Widmer, Reinhard DummerMitchell P Levesque. (2013) Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy 5:2, pages 169-182.
Crossref
Crossref
Marc Mueller, Wilfried Reichardt, Julia Koerner & Marcus Groettrup. (2012) Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. Journal of Controlled Release 162:1, pages 159-166.
Crossref
Crossref
Dodie S Pouniotis, Sandra Esparon, Vasso Apostolopoulos & Geoffrey A Pietersz. (2011)
Whole protein and defined CD8
+
and CD4
+
peptides linked to penetratin targets both MHC class I and II antigen presentation pathways
. Immunology & Cell Biology 89:8, pages 904-913.
Crossref
Crossref
Jonathan Treisman & Nina Garlie. (2010) Systemic Therapy for Cutaneous Melanoma. Clinics in Plastic Surgery 37:1, pages 127-146.
Crossref
Crossref
Irina Luceska. (2009) Therapeutic Cancer Vaccines: Past Situation and Current Developments. Macedonian Journal of Medical Sciences 2:3, pages 261-266.
Crossref
Crossref
Christopher W. Cluff. 2010. Lipid A in Cancer Therapy. Lipid A in Cancer Therapy
111
123
.
Jie Meng, Jie Meng, Jinhong Duan, Hua Kong, Li Li, Chen Wang, Sishen Xie, Shuchang Chen, Ning Gu, Haiyan Xu & Xian-Da Yang. (2008) Carbon Nanotubes Conjugated to Tumor Lysate Protein Enhance the Efficacy of an Antitumor Immunotherapy. Small 4:9, pages 1364-1370.
Crossref
Crossref
Kevin D. Pavelko, Karin L. Heckman, Michael J. Hansen & Larry R. Pease. (2008) An Effective Vaccine Strategy Protective against Antigenically Distinct Tumor Variants. Cancer Research 68:7, pages 2471-2478.
Crossref
Crossref
Pia Kvistborg, Sine Reker Hadrup, Inge Marie Svane, Mads Hald Andersen & Per thor Straten. (2008) Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Human Immunology 69:4-5, pages 266-272.
Crossref
Crossref
H. M. Shepard, P. Jin, D. J. Slamon, Z. Pirot & D. C. Maneval. 2008. Therapeutic Antibodies. Therapeutic Antibodies
183
219
.
Malcolm S. MitchellJudith AbramsJohn A. ThompsonMohammed Kashani-SabetRonald C. DeContiWen-Jen HwuMichael B. AtkinsEric WhitmanMarc S. ErnstoffFrank G. HaluskaJames G. JakowatzTapas K. Das GuptaJon M. RichardsWolfram E. SamlowskiJohn J. CostanziFrederick R. AronsonAlbert B. DeisserothArkadiusz Z. DudekVicky E. Jones. (2007) Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma. Journal of Clinical Oncology 25:15, pages 2078-2085.
Crossref
Crossref
Svetomir N. Markovic, Lori A. Erickson, Ravi D. Rao, Roger H. Weenig, Barbara A. Pockaj, Aditya Bardia, Celine M. Vachon, Steven E. Schild, Robert R. McWilliams, Jennifer L. Hand, Susan D. Laman, Lisa A. Kottschade, William J. Maples, Mark R. Pittelkow, Jose S. Pulido, J. Douglas Cameron & Edward T. Creagan. (2007) Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. Mayo Clinic Proceedings 82:4, pages 490-513.
Crossref
Crossref
N Nakai, T Kishida, M Shin-Ya, J Imanishi, Y Ueda, S Kishimoto & O Mazda. (2006) Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Therapy 14:4, pages 357-365.
Crossref
Crossref
Lance W. U'Ren, Barbara J. Biller, Robyn E. Elmslie, Douglas H. Thamm & Steven W. Dow. (2008) Evaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma. Journal of Veterinary Internal Medicine 21:1, pages 113-120.
Crossref
Crossref
Mike WhelanGraham BallChris BeattieAngus Dalgleish. (2006) Biomarkers for development of cancer vaccines. Personalized Medicine 3:1, pages 79-88.
Crossref
Crossref
Julian A. Kim & Ernest Borden. 2006. From Melanocytes to Melanoma. From Melanocytes to Melanoma
633
649
.
Mads Hald Andersen, Jürgen C. Becker & Per thor Straten. (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nature Reviews Drug Discovery 4:5, pages 399-409.
Crossref
Crossref
Hong-Ming Hu, Yiwei Chu & Walter J. Urba. 2005. Tumor Immunology and Cancer Vaccines. Tumor Immunology and Cancer Vaccines
207
225
.
Samir N. Khleif. 2004. Gynecologic Cancer. Gynecologic Cancer
953
968
.